MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
0.2577
-0.0283
-9.90%
After Hours: 0.2643 +0.0066 +2.56% 17:44 01/22 EST
OPEN
0.2774
PREV CLOSE
0.2860
HIGH
0.2900
LOW
0.2567
VOLUME
730.90K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.2170
MARKET CAP
18.68M
P/E (TTM)
-0.3399
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INAB last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at INAB last week (0106-0110)?
Weekly Report · 01/13 09:36
Weekly Report: what happened at INAB last week (1230-0103)?
Weekly Report · 01/06 09:38
Weekly Report: what happened at INAB last week (1223-1227)?
Weekly Report · 12/30/2024 09:36
Weekly Report: what happened at INAB last week (1216-1220)?
Weekly Report · 12/23/2024 09:38
Weekly Report: what happened at INAB last week (1209-1213)?
Weekly Report · 12/16/2024 09:38
IN8bio Announces Positive Phase 1 Trial Results for INB-100, Demonstrating Durable Complete Remissions in Acute Myeloid Leukemia Patients
Barchart · 12/10/2024 16:18
IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
Benzinga · 12/10/2024 12:06
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Webull offers IN8BIO, Inc. stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.